Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6 cycles followed by bevacizumab until disease progression or a premature drop out of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095

Colorectal Cancer

COMPLETED PHASE3

Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer

NCT01531595

Metastatic Colorectal Cancer

ACTIVE_NOT_RECRUITING PHASE2

A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

NCT01159171

Colorectal Cancer

COMPLETED PHASE2

Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer

NCT00202774

Colorectal Cancer

COMPLETED PHASE3

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

NCT00345696

Metastatic Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6 cycles followed by bevacizumab until disease progression or a premature drop out of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

XELOXA

Group Type ACTIVE_COMPARATOR

XELOXA

Intervention Type DRUG

XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks

2

XELOXA-A

Group Type EXPERIMENTAL

XELOXA-A

Intervention Type DRUG

XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.

One cycle every 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XELOXA

XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks

Intervention Type DRUG

XELOXA-A

XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.

One cycle every 3 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent given.
* Patients who are able to understand the study request.
* Men and women \> or = 18 years, not hospitalized.
* Outpatients with ECOG performance status ≤ 2.
* Histologically confirmed diagnosis of colorectal cancer (CRC) patients with metastasis.
* Presence of at least one detectable lesion in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
* Life expectancy of greater than 3 months.
* Men and women potentially fertile using an effective contraceptive method

Exclusion Criteria

* Patients who have been treated with bevacizumab previously.
* Received any systemic treatment previously to treat an advanced or metastatic disease

* Adjuvant or neoadjuvant treatment to non-metastatic disease is allowed, provided that it has been finished at least 6 months before the initial study treatment.
* If the patient has been treated with adjuvant therapy previously, it is not allowed to be included in the study in case of disease progression during treatment or for 6 months after the end of treatment.
* If radiotherapy has not been administered in the lesion selected for the study, previous radiotherapy is allowed, unless progression of those injuries can be documented in the radiated field, as long as the end of the treatment has been finished at least 4 weeks before study initiation.
* Previous surgical procedure of stage IV disease is allowed.
* Previous malignancies other than adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or this study indication, unless there has been a disease-free interval of at least 2 years.
* History or evidence upon physical examination of central nervous system
* History of psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
* Clinically significant cardiovascular disease (active).
* Patients who have undergone myocardial infarction or cerebrovascular accident 6 months prior to randomisation will be excluded.
* Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome or inability to take oral medications.
* Patients subjected to allogeneic transplant and request immunotherapy.
* Bone fracture not healed, wounds or severe ulcers.
* Known hemorrhagic diathesis or coagulopathy.
* Uncontrolled and severe intercurrent infections or other severe and uncontrolled concomitant diseases.
* Moderate or severe renal impairment (creatinine clearance \< 30 ml/min \[calculated according to Cockroft-Gault formula\] or serum creatinine ≥ 2 mg/dl or 177 μmol/l).
* Any of the following laboratory values:

* Absolute neutrophil count (ANC) ≤ 1.5 x 10\^9/l.
* Platelet count ≤ 100 x 10\^9/l.
* Hemoglobin ≤ 9 g/dl.
* International Normalized Ratio (INR) ≥ 1.5.
* Total bilirubin ≥ 1.5 x upper limit of normal (ULN).
* ALT and/or AST ≥ 2.5 x ULN or ≥ 5 x ULN (in case of hepatic metastasis).
* Alkaline phosphatase \> 2.5 x ULN or 5 x ULN (in case of hepatic metastasis), or \> 10 x ULN (in case of bone metastasis).
* History of unexpected serious adverse events to fluoropyrimidine treatments or known dihydropyrimidine dehydrogenase (DPD) deficiency.
* Patients subjected to major surgical procedure or open biopsy; or patients have had significant traumatic injuries 28 days before the initial study treatment; or patients with a major surgical procedure planned during the study period.
* Fine needle aspiration biopsy 7 days before study initiation.
* Use of full dose of oral or parenteral anticoagulants (at least 10 days before the initial study treatment) or thrombolytic agents. Low dose of warfarin is allowed, with an INR ≤ 1.5.
* Subjects requiring chronic use of high dose aspirin (\> 325 mg/day) or non-steroidal anti-inflammatory treatment (those known to inhibit platelet function at doses used to treat chronic inflammatory diseases).
* Pregnant or lactating women.
* Patients with known allergy to Chinese hamster ovary cell proteins or other recombinant human or humanized antibodies; or to any excipients of bevacizumab formulation; or to any other study drugs.
* Received any investigational drug or agent/procedure, i.e. participation in another treatment trial within 30 days of randomisation.
* Evidence of another disease, metabolic malfunction, discovery in a physical examination or in a clinical laboratory test to result in reasonable suspicion of a condition or disease that contraindicates investigational medicine use or exposes the patient to high risk treatment complications.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No